30 results
8-K
COGT
Cogent Biosciences Inc
11 Dec 23
Other Events
8:04am
for bezuclastinib’s safety and tolerability profile to support chronic dosing for patients with NonAdvSM; plans for the Company to initiate Part 2 of SUMMIT
424B5
COGT
Cogent Biosciences Inc
15 Jun 22
Prospectus supplement for primary offering
5:16pm
on study. Subsequently, one SM-AHN patient with chronic myelomonocytic leukemia (CMML) transformed to acute myeloid leukemia (AML) and discontinued
424B5
COGT
Cogent Biosciences Inc
13 Jun 22
Prospectus supplement for primary offering
6:11am
, all patients remained on study. Subsequently, one SM-AHN patient with chronic myelomonocytic leukemia (CMML) transformed to acute myeloid leukemia (AML
8-K
EX-99.1
zg0zt6eo7b7ttz
10 Jun 22
Submission of Matters to a Vote of Security Holders
7:12am
8-K
EX-99.2
y1kbz17
10 Jun 22
Submission of Matters to a Vote of Security Holders
7:12am
424B5
i9r3m3qds4afkanyfre8
2 Dec 20
Prospectus supplement for primary offering
5:06pm
424B5
lbtah0 hg
30 Nov 20
Prospectus supplement for primary offering
5:28pm
DEFM14A
ftudt
9 Oct 20
Proxy related to merger
4:44pm
8-K
EX-99.2
npgy 2piqqo27yiicc
5 Oct 20
Unum Therapeutics Announces Company Name Change to Cogent Biosciences, Highlights Recent Scientific and Operational Progress
9:08am
8-K
EX-99.1
tnsoq 9eck
11 Aug 20
Unum Therapeutics Reports Second Quarter 2020
5:02pm
8-K
EX-99.2
5iw5f9pxf
6 Jul 20
Unum Therapeutics Inc. Announces Acquisition of Kiq LLC
10:31am